Edgewise Therapeutics, Inc.
EWTX
Rang in aandelen
#3850
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Aandeelprijs
$39.70
Laatst gesynchroniseerd: 2026-10-21
Marktkapitalisatie
$4.27B
Verandering (1 dag)
-0.12%
Verandering (1 jaar)
166.64%
Land
US
Handel Edgewise Therapeutics, Inc. (EWTX)
Categorie
Healthcare
Koersgeschiedenis voor Edgewise Therapeutics, Inc. (EWTX)
Hoogste slotkoers: $38.97 op 2026-10-01
Laagste slotkoers: $32.43 op 2021-03-01
Laagste slotkoers: $32.43 op 2021-03-01
Koersgeschiedenis van Edgewise Therapeutics, Inc. van 2021 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | 38.00% |
| 2025 | -20.97% |
| 2024 | 268.96% |
| 2023 | -1.80% |
| 2022 | -51.10% |
| 2021 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.63 | -3.92% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
